Lacosamid Stada

Lacosamide, the active ingredient in Lacosamid Stada, is a sodium channel blocker presented as an oral formulation for oral use. It is used as adjunctive therapy for partial‑onset seizures in patients with epilepsy. GNH USA supplies Lacosamid Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic medication that targets voltage‑gated sodium channels to control seizures.

Partial‑onset seizures: adjunctive therapy to reduce seizure frequency in patients with epilepsy. Focal seizures: improves seizure control in individuals with focal epilepsy. Epilepsy: used as part of combination therapy for overall seizure management.

Lacosamide may cause a range of adverse reactions, some of which are more frequent than others.

Common Side Effects: - Dizziness - Fatigue - Nausea - Headache - Diplopia (double vision) - Somnolence

Serious or Rare Side Effects: - Cardiac conduction abnormalities (e.g., PR‑interval prolongation) - Severe skin reactions such as Stevens‑Johnson syndrome - Suicidal thoughts or behavior - Hypersensitivity reactions including anaphylaxis - Hepatic injury - Aseptic meningitis

When prescribing Lacosamide, several safety considerations should be observed.

Dose titration: start with a low dose and increase gradually as directed by the prescriber. Renal impairment: assess renal function and adjust dosing if necessary. Hepatic impairment: monitor liver enzymes and consider dose modification. Concomitant CNS depressants: may increase sedation and dizziness. Pregnancy: risk unknown; use only if potential benefit justifies the risk. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Lacosamide can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Carbamazepine: may lower lacosamide plasma concentrations. - Phenytoin: can reduce lacosamide exposure. - Rifampin: may decrease lacosamide levels. - Strong CYP3A4 inhibitors: may raise lacosamide concentrations. - Drugs that prolong PR interval: increase risk of cardiac conduction effects.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs: additive CNS depression may occur. - Alcohol: can enhance sedative effects. - Opioids: may increase risk of respiratory depression.